Lung Cancer

PV QA 4 - Poster Viewing Q&A 4

TU_28_3594 - Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy

Tuesday, October 23
2:45 PM - 4:15 PM
Location: Innovation Hub, Exhibit Hall 3

Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy
N. Giaj-Levra1,2, M. Trovo3, E. Muraro4, S. Fersino2, A. Fiorentino5, R. Mazzola5, F. Ricchetti5, A. R. Filippi1, U. Ricardi1, and F. Alongi2,6; 1Department of Oncology, University of Torino, Torino, Italy, 2Department of Radiation Oncology, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy, 3Department of Radiation Oncology, Udine General Hospital, Udine, Italy, 4Immunopathology and Biomarker Unit, Department of Translational Research, Centro di Riferimento Oncologico, Aviano, Italy, 5Radiation Oncology Dept, Sacro Cuore - don Calabria Hospital, Negrar (VR), Italy, 6University of Brescia, Brescia, Italy

Purpose/Objective(s): To estimate the prognostic role of plasmatic levels of IL-13 in patients with early stage non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiation therapy (SABR).

Materials/Methods: Fifteen patients were prospectively enrolled in this pilot study from January 2010 to December 2012. Blood samples were collected at the following time: first day of SABR (TFd), last day of SABR (TLd) and 45 days (T45d) after the end of SABR. Firstly, we aimed to investigate whether IL-13 levels were associated with cancer specific survivals (CSS). Secondly, we tested if different IL-13 levels might identify specific subgroups of patients at higher risk of radiation-induced lung toxicity.

Results: All patients received a radiation dose prescription of 52 Gy in 8 fractions for stage IA-B NSCLC. IL-13 levels, measured at TFd (p=0.038) and T45d, resulted significantly associated with lower CSS (p=0.045). Additionally, a trend of correlation between IL-13 levels at T45d and late moderate-severe chronic radiological lung injury was also observed (p= 0.06)

Conclusion: The results of this pilot study suggest that IL-13 levels may correlate with lower CSS and a higher incidence of late moderate-severe lung toxicity. A larger sample size is needed to confirm or not this hypothesis.

Author Disclosure: N. Giaj-Levra: None. M. Trovo: None. E. Muraro: None. S. Fersino: None. F. Ricchetti: None.

Send Email for Niccol? Giaj-Levra


Assets

TU_28_3594 - Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Report of a Pilot Study on IL-13 As Prognostic Biomarker in Patients with Early Stage Lung Cancer Treated with Stereotactic Ablative Radiation Therapy